Published: 30 Apr 2023 | Report Code: 10248391 | Pages: 196
Asia Pacific Active Pharmaceutical Ingredients (API) Market will grow by 8.1% annually with a total addressable market cap of $ 1,098.6 billion over 2023-2032, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in the geriatric population. Highlighted with 88 tables and 75 figures, this 196-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific Active Pharmaceutical Ingredients (API) Market and all its sub-segments through extensively detailed classifications.
Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include the identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Five Forces
The trend and outlook of the Asia Pacific market is forecast in an optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific Active Pharmaceutical Ingredients (API) Market in every aspect of the classification from perspectives of Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Molecule, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Small Molecule APIs
• Large Molecule APIs
Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Biotech API
o By Type
o Monoclonal Antibodies
o Recombinant Proteins
o Vaccines
o Other Biotech APIs
o By Category
o Innovative Biologic API
o Generic Biosimilar API
o By Expression
o Mammalian Expression
o Microbial Expression
o Yeast Expression
o Insect Expression
o Other Expression Technologies
• HPAPI
o Branded HPAPI
o Generic HPAPI
Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Captive Manufacturing
o Branded Captive API
o Generic Captive API
• Merchant Manufacturing
o By Drug Type
o Branded Merchant API
o Generic Merchant API
o By Drug Synthesis
o Merchant Synthetic API
o Merchant Biotech API
By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications
By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents: 1 Introduction 9 1.1 Industry Definition and Research Scope 9 1.1.1 Industry Definition 9 1.1.2 Research Scope 10 1.2 Research Methodology 13 1.2.1 Overview of Market Research Methodology 13 1.2.2 Market Assumption 14 1.2.3 Secondary Data 14 1.2.4 Primary Data 14 1.2.5 Data Filtration and Model Design 15 1.2.6 Market Size/Share Estimation 16 1.2.7 Research Limitations 17 1.3 Executive Summary 18 2 Market Overview and Dynamics 21 2.1 Market Size and Forecast 21 2.1.1 Impact of COVID-19 on World Economy 22 2.1.2 Impact of COVID-19 on the Market 25 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 32 2.2 Major Growth Drivers 36 2.3 Market Restraints and Challenges 44 2.4 Emerging Opportunities and Market Trends 47 2.5 Porter’s Fiver Forces Analysis 51 3 Segmentation of Asia Pacific Market by Molecule 55 3.1 Market Overview by Molecule 55 3.2 Small Molecule APIs 57 3.3 Large Molecule APIs 58 4 Segmentation of Asia Pacific Market by Synthesis 59 4.1 Market Overview by Synthesis 59 4.2 Synthetic API 61 4.2.1 Branded Synthetic API 62 4.2.2 Generic Synthetic API 63 4.3 Biotech API 64 4.3.1 Biotech API by Drug Type 65 4.3.1.1 Monoclonal Antibodies 66 4.3.1.2 Recombinant Proteins 67 4.3.1.3 Vaccines 68 4.3.1.4 Other Biotech APIs 69 4.3.2 Biotech API by Category 70 4.3.2.1 Innovative Biologic API 71 4.3.2.2 Generic Biosimilar API 72 4.3.3 Biotech API by Expression Technology 73 4.3.3.1 Mammalian Expression 74 4.3.3.2 Microbial Expression 75 4.3.3.3 Yeast Expression 76 4.3.3.4 Insect Expression 77 4.3.3.5 Other Expression Technologies 78 4.4 HPAPI 79 4.4.1 Branded HPAPI 80 4.4.2 Generic HPAPI 81 5 Segmentation of Asia Pacific Market by Manufacturing Process 82 5.1 Market Overview by Manufacturing Process 82 5.2 Captive Manufacturing 84 5.2.1 Branded Captive API 85 5.2.2 Generic Captive API 86 5.3 Merchant Manufacturing 87 5.3.1 Merchant Manufacturing by Drug Type 88 5.3.1.1 Branded Merchant API 89 5.3.1.2 Generic Merchant API 90 5.3.2 Merchant Manufacturing by Drug Synthesis 91 5.3.2.1 Merchant Synthetic API 92 5.3.2.2 Merchant Biotech API 93 6 Segmentation of Asia Pacific Market by Therapeutic Application 94 6.1 Market Overview by Therapeutic Application 94 6.2 Infectious Diseases 96 6.3 Oncology 97 6.4 Ophthalmology 98 6.5 Cardiovascular Disorders 99 6.6 Central Nervous System 100 6.7 Pulmonary Disorders 101 6.8 Orthopedics 102 6.9 Other Applications 103 7 Segmentation of Asia Pacific Market by Drug Type 104 7.1 Market Overview by Drug Type 104 7.2 Branded Prescription Drugs 106 7.3 Generic Prescription Drugs 107 7.4 OTC Drugs 108 8 Asia-Pacific Market 2022-2032 by Country 109 8.1 Overview of Asia-Pacific Market 109 8.2 China 112 8.3 Japan 114 8.4 India 117 8.5 Australia 119 8.6 South Korea 121 8.7 Rest of APAC Region 123 9 Competitive Landscape 125 9.1 Overview of Key Vendors 125 9.2 New Product Launch, Partnership, Investment, and M&A 128 9.3 Company Profiles 129 AbbVie Inc. 129 Astrazeneca 131 Aurobindo Pharma Ltd. 136 BASF 139 Bayer AG 142 Boehringer Ingelheim 146 Catalent Inc. 151 Dr. Reddy's Laboratories 154 F. Hoffmann-La Roche 156 GlaxoSmithKline plc 159 Lonza Group 164 Lupin Limited 168 Merck & Co., Inc. 171 Mylan NV 174 Novartis International AG 177 Pfizer Inc. 180 Sanofi 185 Sun Pharmaceutical Industries Ltd. 188 Teva Pharmaceutical Industries Ltd. 191 Thermo Fisher Scientific 193 Related Reports and Products 196
List of Tables: Table 1. Snapshot of Asia Pacific Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2022-2032 19 Table 2. World Economic Outlook, 2021-2031 23 Table 3. World Economic Outlook, 2021-2023 24 Table 4. Scenarios for Economic Impact of Ukraine Crisis 33 Table 5. World Health Spending by Region, $ bn, 2013-2020 42 Table 6. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 43 Table 7. Main Product Trends and Market Opportunities in Asia Pacific Active Pharmaceutical Ingredients (API) Market 47 Table 8. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, $ bn 55 Table 9. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 59 Table 10. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2022-2032, $ bn 61 Table 11. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2022-2032, $ bn 65 Table 12. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Category, 2022-2032, $ bn 70 Table 13. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2022-2032, $ bn 73 Table 14. Asia Pacific Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2022-2032, $ bn 79 Table 15. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 82 Table 16. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2022-2032, $ bn 84 Table 17. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2022-2032, $ bn 88 Table 18. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2022-2032, $ bn 91 Table 19. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 94 Table 20. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, $ bn 104 Table 21. APAC Active Pharmaceutical Ingredients (API) Market by Country, 2022-2032, $ bn 110 Table 22. China Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 113 Table 23. China Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 113 Table 24. China Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 113 Table 25. Japan Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 116 Table 26. Japan Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 116 Table 27. Japan Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 116 Table 28. India Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 118 Table 29. India Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 118 Table 30. India Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 118 Table 31. Australia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 120 Table 32. Australia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 120 Table 33. Australia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 120 Table 34. South Korea Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 122 Table 35. South Korea Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 122 Table 36. South Korea Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 122 Table 37. Active Pharmaceutical Ingredients (API) Market in Rest of APAC by Country, 2022-2032, $ bn 124 Table 38. AbbVie Inc.: Company Snapshot 129 Table 39. AbbVie Inc.: Business Segmentation 130 Table 40. AbbVie Inc.: Product Portfolio 130 Table 41. Astrazeneca: Company Snapshot 131 Table 42. Aurobindo Pharma Ltd.: Company Snapshot 136 Table 43. Aurobindo Pharma Ltd.: Product Portfolio 137 Table 44. BASF: Company Snapshot 139 Table 45. BASF: Business Segmentation 140 Table 46. Bayer AG: Company Snapshot 142 Table 47. Bayer AG: Business Segmentation 143 Table 48. Bayer AG: Product Portfolio 143 Table 49. Boehringer Ingelheim: Company Snapshot 146 Table 50. Boehringer Ingelheim: Product Portfolio 147 Table 51. Catalent Inc.: Company Snapshot 151 Table 52. Catalent Inc.: Business Segmentation 152 Table 53. Catalent Inc.: Product Portfolio 152 Table 54. Dr. Reddy's Laboratories: Company Snapshot 154 Table 55. Dr. Reddy's Laboratories: Business Segmentation 154 Table 56. F. Hoffmann-La Roche: Company Snapshot 156 Table 57. F. Hoffmann-La Roche: Clinical Trial Service 156 Table 58. F. Hoffmann-La Roche: Business Segmentation 157 Table 59. F. Hoffmann-La Roche: Revenue by Region 157 Table 60. GlaxoSmithKline: Company Snapshot 159 Table 61. GlaxoSmithKline: Business Segmentation 160 Table 62. GlaxoSmithKline: Product Portfolio 161 Table 63. Lonza Group: Company Snapshot 164 Table 64. Lonza Group: Business Segmentation 165 Table 65. Lonza Group: Product Portfolio 165 Table 66. Lupin Limited: Company Snapshot 168 Table 67. Lupin Limited: Business Segmentation 169 Table 68. Merck & Co., Inc.: Company Snapshot 171 Table 69. Merck & Co., Inc.: Business Segmentation 172 Table 70. Mylan NV: Company Snapshot 174 Table 71. Mylan NV: Breakdown of Revenue by Region, 2022 175 Table 72. Mylan NV: Breakdown of Revenue by Product Category, 2022 175 Table 73. Novartis International AG: Company Snapshot 177 Table 74. Novartis International AG: Business Segmentation 178 Table 75. Pfizer Inc.: Company Snapshot 180 Table 76. Pfizer Inc.: Business Segmentation 181 Table 77. Pfizer Inc.: Breakdown of Revenue by Product Category 181 Table 78. Pfizer Inc.: Breakdown of Revenue by Region 182 Table 79. Pfizer Inc.: Product Portfolio 182 Table 80. Sanofi: Company Snapshot 185 Table 81. Sanofi: Business Segmentation 186 Table 82. Sanofi: Breakdown of Revenue by Region 186 Table 83. Sun Pharmaceutical Industries Limited: Company Snapshot 188 Table 84. Teva Pharmaceutical Industries Ltd.: Company Snapshot 191 Table 85. Teva Pharmaceutical Industries Ltd.: Business Segmentation 192 Table 86. Thermo Fisher Scientific: Company Snapshot 193 Table 87. Thermo Fisher Scientific: Breakdown of Revenue by Business Segment, 2020, 4 Table 88. Thermo Fisher Scientific: Breakdown of Revenue by Region, 2020, 4
List of Figures: Figure 1. Research Method Flow Chart 13 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16 Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 18 Figure 4. Asia Pacific Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 21 Figure 5. Impact of COVID-19 on Business 25 Figure 6. Primary Drivers and Impact Factors of Asia Pacific Active Pharmaceutical Ingredients (API) Market 36 Figure 7. GDP per capita in the World, 1960-2022, $ thousand 39 Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 40 Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 41 Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 41 Figure 11. Primary Restraints and Impact Factors of Asia Pacific Active Pharmaceutical Ingredients (API) Market 44 Figure 12. Investment Opportunity Analysis 48 Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Active Pharmaceutical Ingredients (API) Market 51 Figure 14. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, % of Revenue 56 Figure 15. Asia Pacific Addressable Market Cap in 2023-2032 by Molecule, Value ($ bn) and Share (%) 56 Figure 16. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule: Small Molecule APIs, 2022-2032, $ bn 57 Figure 17. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule: Large Molecule APIs, 2022-2032, $ bn 58 Figure 18. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, % of Revenue 59 Figure 19. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 60 Figure 20. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis: Synthetic API, 2022-2032, $ bn 61 Figure 21. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthetic API: Branded Synthetic API, 2022-2032, $ bn 62 Figure 22. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthetic API: Generic Synthetic API, 2022-2032, $ bn 63 Figure 23. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis: Biotech API, 2022-2032, $ bn 64 Figure 24. Asia Pacific Biotech API Market by Drug Type: Monoclonal Antibodies, 2022-2032, $ bn 66 Figure 25. Asia Pacific Biotech API Market by Drug Type: Recombinant Proteins, 2022-2032, $ bn 67 Figure 26. Asia Pacific Biotech API Market by Drug Type: Vaccines, 2022-2032, $ bn 68 Figure 27. Asia Pacific Biotech API Market by Drug Type: Other Biotech APIs, 2022-2032, $ bn 69 Figure 28. Asia Pacific Biotech API Market by Category: Innovative Biologic API, 2022-2032, $ bn 71 Figure 29. Asia Pacific Biotech API Market by Category: Generic Biosimilar API, 2022-2032, $ bn 72 Figure 30. Asia Pacific Biotech API Market by Expression Technology: Mammalian Expression, 2022-2032, $ bn 74 Figure 31. Asia Pacific Biotech API Market by Expression Technology: Microbial Expression, 2022-2032, $ bn 75 Figure 32. Asia Pacific Biotech API Market by Expression Technology: Yeast Expression, 2022-2032, $ bn 76 Figure 33. Asia Pacific Biotech API Market by Expression Technology: Insect Expression, 2022-2032, $ bn 77 Figure 34. Asia Pacific Biotech API Market by Expression Technology: Other Expression Technologies, 2022-2032, $ bn 78 Figure 35. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis: HPAPI, 2022-2032, $ bn 79 Figure 36. Asia Pacific Active Pharmaceutical Ingredients (API) Market by HPAPI: Branded HPAPI, 2022-2032, $ bn 80 Figure 37. Asia Pacific Active Pharmaceutical Ingredients (API) Market by HPAPI: Generic HPAPI, 2022-2032, $ bn 81 Figure 38. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, % of Revenue 82 Figure 39. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 83 Figure 40. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Captive Manufacturing, 2022-2032, $ bn 84 Figure 41. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Branded Captive API, 2022-2032, $ bn 85 Figure 42. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Generic Captive API, 2022-2032, $ bn 86 Figure 43. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Merchant Manufacturing, 2022-2032, $ bn 87 Figure 44. Asia Pacific API Merchant Manufacturing Market by Drug Type: Branded Merchant API, 2022-2032, $ bn 89 Figure 45. Asia Pacific API Merchant Manufacturing Market by Drug Type: Generic Merchant API, 2022-2032, $ bn 90 Figure 46. Asia Pacific API Merchant Manufacturing Market by Drug Synthesis: Merchant Synthetic API, 2022-2032, $ bn 92 Figure 47. Asia Pacific API Merchant Manufacturing Market by Drug Synthesis: Merchant Biotech API, 2022-2032, $ bn 93 Figure 48. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, % of Revenue 94 Figure 49. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 95 Figure 50. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Infectious Diseases, 2022-2032, $ bn 96 Figure 51. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Oncology, 2022-2032, $ bn 97 Figure 52. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Ophthalmology, 2022-2032, $ bn 98 Figure 53. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Cardiovascular Disorders, 2022-2032, $ bn 99 Figure 54. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Central Nervous System, 2022-2032, $ bn 100 Figure 55. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Pulmonary Disorders, 2022-2032, $ bn 101 Figure 56. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Orthopedics, 2022-2032, $ bn 102 Figure 57. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Other Applications, 2022-2032, $ bn 103 Figure 58. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, % of Revenue 104 Figure 59. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 105 Figure 60. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type: Branded Prescription Drugs, 2022-2032, $ bn 106 Figure 61. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type: Generic Prescription Drugs, 2022-2032, $ bn 107 Figure 62. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type: OTC Drugs, 2022-2032, $ bn 108 Figure 63. Breakdown of APAC Active Pharmaceutical Ingredients (API) Market by Country, 2022 and 2032, % of Revenue 110 Figure 64. Contribution to APAC 2023-2032 Cumulative Revenue by Country, Value ($ bn) and Share (%) 111 Figure 65. Active Pharmaceutical Ingredients (API) Market in China, 2022-2032, $ bn 112 Figure 66. Active Pharmaceutical Ingredients (API) Market in Japan, 2022-2032, $ bn 115 Figure 67. Active Pharmaceutical Ingredients (API) Market in India, 2022-2032, $ bn 117 Figure 68. Active Pharmaceutical Ingredients (API) Market in Australia, 2022-2032, $ bn 119 Figure 69. Active Pharmaceutical Ingredients (API) Market in South Korea, 2022-2032, $ bn 121 Figure 70. Active Pharmaceutical Ingredients (API) Market in Rest of APAC, 2022-2032, $ bn 123 Figure 71. Growth Stage of Asia Pacific Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 125 Figure 72. AstraZeneca: Breakdown of Revenue by Therapy Area, 2022 132 Figure 73. AstraZeneca: Breakdown of Revenue by Region, 2022 132 Figure 74. Boehringer Ingelheim: Revenue by Business Segment, 2019-2022 147 Figure 75. Boehringer Ingelheim: R&D Investement, 2019-2022 148
Selected Key Players: AbbVie Inc. Astrazeneca Aurobindo Pharma Ltd. BASF Bayer AG Boehringer Ingelheim Catalent Inc. Dr. Reddy's Laboratories F. Hoffmann-La Roche GlaxoSmithKline plc Lonza Group Lupin Limited Merck & Co., Inc. Mylan NV Novartis International AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)